Beyond HbA1c: Take a Global Approach to Type 2 Diabetes Management, Use all the Tools
July 01, 2022

Drs Mikhail Kosiborod and Neil Skolnik discuss this unique moment in the history of T2D management that offers treatments to address its broad cardiometabolic impact.

US Cardiovascular Health Remains Poor, Declines Begin in Early Childhood: American Heart Association Investigators
June 29, 2022

US CV health is well below ideal, with 80% of adults scoring as only low or moderate in the first published study using AHA's new Life's Essential 8 algorithm.

American Heart Association Announces "Life's Essential 8" Enhanced Cardiovascular Health Model
June 29, 2022

Slide Show: The AHA added sleep duration to its Life's Simple 7 cardiovascular health construct and updated sections on diet, lipids, blood glucose and smoking.

Lessons Learned from the VA on Delay in Second-line Treatment for Type 2 Diabetes
June 28, 2022

Lead author of a study of nearly 200 000 adults with type 2 diabetes that revealed significant clinical inertia in the critical period following initial diagnosis expands on the implications.

Perceived Risk for Diabetes Low among Racial/Ethnic Minorities with Undiagnosed Prediabetes
June 27, 2022

Non-Hispanic Black and Hispanic adults with undiagnosed prediabetes are less likely than White adults to appreciate their risk for overt type 2 diabetes.

VA Clinical Investigator Discusses HbA1c, Comorbidities as Markers for T2D Treatment Intensification
June 24, 2022

Change in HbA1c as a guide for T2D treatment intensification is steadily yielding to presence of/risk for comorbidities as pluripotent agents win guideline favor, observes a VA clinical investigator.

Cost of CGM Must be Covered in Illinois, Pursuant to June 15th Legislation
June 21, 2022

The cost of continuous glucose monitors must be covered for persons with type 1 and type 2 diabetes in the state of Illinois based on a bill signed into law this month.

Clinician Bias May be a Factor in Underdiagnoses of Prediabetes, According to Research Presented at ENDO 2022
June 17, 2022

ENDO 2022. Age, body mass index, gender, race, and certain comorbidities may influence a diagnosis of prediabetes in primary care settings, suggests new study.

Empagliflozin Could Reduce Risk of Kidney Stones in Patients with Type 2 Diabetes
June 17, 2022

Empagliflozin was associated with a nearly 40% reduced risk of incident renal stone disease vs placebo in a large analysis of data pooled from randomized clinical trials.